Results 251 to 260 of about 10,651,893 (289)

Antiangiogenic Activity of Alofanib, an Allosteric Inhibitor of Fibroblast Growth Factor Receptor 2

Bulletin of Experimental Biology and Medicine, 2015
Alofanib is a potential allosteric inhibitor of FGFR2 used in oncology. The inhibitor blocks the extracellular part of the receptor and prevents its binding with the ligand. Alofanib suppressed proliferation of endothelial cells, their migration activity, and ability to form vessellike structures in vitro and significantly decreased the number of ...
D A, Khochenkov, E Sch, Solomko, N M, Peretolchina, O O, Ryabaya, E V, Stepanova   +4 more
openaire   +2 more sources

Fibroblast Growth Factor Receptor Inhibitors and Nonuremic Calciphylaxis

JAMA Dermatology, 2021
Jesse, Hirner, James M, Cleary, Anthony, Sheets, George, Murphy, Nicole, LeBoeuf   +4 more
openaire   +2 more sources

Fibroblast growth factor receptor 1 is a key inhibitor of TGFβ signaling in the endothelium

Science Signaling, 2014
Endothelial-to-mesenchymal transition is suppressed by FGFR1 signaling.
Pei-Yu, Chen, Lingfeng, Qin, George, Tellides, Michael, Simons   +3 more
openaire   +2 more sources

Management of Nail Toxicities From Fibroblast Growth Factor Receptor Inhibitors

Journal of Drugs in Dermatology
Alterations in fibroblast growth factor receptor (FGFR) signaling are present in many malignancies, including urothelial carcinoma, cholangiocarcinoma, and gastrointestinal cancers, and FGFR inhibitors (FGFRi) play an increasing role in the treatment of these malignancies.
Aneri Bhargav, Patel, Xiying, Fan, Janellen, Smith   +2 more
openaire   +2 more sources

Fibroblast growth factor receptor inhibitor-induced hyperphosphatemia: Lessons for the nephrologist

Clinical Nephrology
Fibroblast growth factor inhibitors (FGFRi) are novel cancer drugs that offer new hope for patients with advanced biliary tract cancers and metastatic urothelial tumors. Despite their effectiveness, they often cause hyperphosphatemia.We investigated the incidence and characteristics of hyperphosphatemia in patients treated with FGFRi at Northwell ...
Rose Mary, Attieh, Pratap, Upadrista, Anna T, Levy, Kenar D, Jhaveri   +3 more
openaire   +2 more sources

Fibroblast Growth Factor Receptor Inhibitor–Associated Retinopathy

JAMA Ophthalmology, 2020
Deep, Parikh, Dean, Eliott, Leo A, Kim
openaire   +2 more sources

Systemic Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Stage and Metastatic Breast Cancer

Ca-A Cancer Journal for Clinicians, 2023
Hope Rugo, Özge Gümüşay, Laura A Huppert   +2 more
exaly  

Hyperphosphatemia in the Setting of Fibroblast Growth Factor Receptor Inhibitors

Journal of the American Society of Nephrology, 2020
Shahrzad Zonoozi, Bader Kfoury, Abdallah Sassine Geara   +2 more
openaire   +1 more source

The Clinical Landscape of HDAC Inhibitors

Medical Epigenetics, 2021
Arasu Ganesan
exaly  

Treatment of Muscle-Invasive and Advanced Bladder Cancer in 2020

Ca-A Cancer Journal for Clinicians, 2020
William K. Oh, Matthew D Galsky, Vaibhav G Patel   +2 more
exaly